Eledon Pharmaceuticals, Inc.ELDNNASDAQ
LOADING
|||
Operating Income Growth Accelerating
Trending higher, above historical average, modest growth trend.
Left:
||||
Year-over-year operating income growth rate
Latest
22.90%
↑ 420% above average
Average (39q)
-7.15%
Historical baseline
Range
High:59.60%
Low:-163.65%
CAGR
+3.1%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | 22.90% |
| Q2 2025 | -37.68% |
| Q1 2025 | 27.26% |
| Q4 2024 | -20.41% |
| Q3 2024 | -41.43% |
| Q2 2024 | -33.43% |
| Q1 2024 | -5.14% |
| Q4 2023 | 7.68% |
| Q3 2023 | -8.15% |
| Q2 2023 | 6.80% |
| Q1 2023 | -10.66% |
| Q4 2022 | 5.27% |
| Q3 2022 | -14.17% |
| Q2 2022 | 5.84% |
| Q1 2022 | -5.05% |
| Q4 2021 | 10.67% |
| Q3 2021 | -31.80% |
| Q2 2021 | 11.48% |
| Q1 2021 | -59.16% |
| Q4 2020 | -163.65% |
| Q3 2020 | -2.14% |
| Q2 2020 | 37.80% |
| Q1 2020 | -46.87% |
| Q4 2019 | 21.23% |
| Q3 2019 | 28.59% |
| Q2 2019 | 16.12% |
| Q1 2019 | -6.51% |
| Q4 2018 | -30.81% |
| Q3 2018 | -9.72% |
| Q2 2018 | -14.10% |
| Q1 2018 | -32.78% |
| Q4 2017 | 29.01% |
| Q3 2017 | 55.52% |
| Q2 2017 | -71.27% |
| Q1 2017 | -3.51% |
| Q4 2016 | 59.60% |
| Q3 2016 | 31.43% |
| Q2 2016 | -18.25% |
| Q1 2016 | -3.68% |
| Q4 2015 | 7.01% |